Waters (WAT) Stock Could Be Cheap On Q2 Earnings Expectations
Waters stock has delivered a 54.3% return over the past three years, while valuation signals are split. A Discounted Cash Flow (DCF) intrinsic value estimate suggests upside, and market multiples point to a richer price tag.
- That 54.3% three-year gain puts recent enthusiasm for Waters front and center and raises the question of how much of the story is already reflected in the share price.
- Expectations for revenue growth, helped by investor focus on upcoming results, can support the intrinsic value case. However, any disappointment in future organic growth or margin trends may weigh on how much investors are willing to pay for the stock.
- Waters only passes 1 out of 6 valuation checks, which leans more towards the stock being expensive than a clear bargain on the broader measures.
The issue now is whether that 17.5% DCF implied discount offers enough margin of safety when some of the other valuation frameworks are more cautious on Waters.
Is Waters a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Waters is worth based on the cash it can generate in the future. For Waters, the model starts with latest twelve month free cash flow of about $365 million and then assumes that free cash flow grows over time rather than staying flat or declining.
On these assumptions, the 2 Stage Free Cash Flow to Equity model points to an intrinsic value of about $500 per share. That sits roughly 17.5% above the current share price, which implies the stock appears undervalued on this cash flow view. The recent focus on Waters Corporation Q2 results, where analysts are looking for very strong year on year revenue growth, helps explain why some investors may be willing to underwrite these higher future cash flow levels.
Taking the DCF output at face value, Waters stock currently screens as undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Waters is undervalued by 17.5%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.
Does Waters Look Pricey on Sales?
P/S is often a useful lens for Waters because revenue is a cleaner starting point than earnings when margins and capital intensity can shift over time. Right now the stock trades on a P/S of 8.7x, which is above both the Life Sciences industry average of 4.1x and the peer group average of 5.3x.
The fair P/S ratio implied by the model is 7.2x. That sits below the current 8.7x level, which suggests investors are paying a richer price for each dollar of Waters revenue than the company specific profile would point to. In other words, even after accounting for its size, sector and risk characteristics, the stock screens as expensive on sales compared with where a more neutral multiple would land.
On the P/S framework, Waters stock currently looks overvalued relative to both its sector and its modelled fair value multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Waters Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this Waters valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each Waters narrative ties a fair value estimate to a particular mix of potential catalysts and risks, so you can track over time which version of the story appears closer to how the business is actually unfolding on the Community page.
The community is split on Waters, with one camp seeing meaningful upside potential and the other warning that risks could justify a tighter valuation.
Bull case: 13% undervalued
"The transformative acquisition of BD's Biosciences and Diagnostic Solutions segment creates an underappreciated step-change in Waters' long-term growth and margin profile, with a credible path to high-single-digit revenue compound growth and mid-teens EPS CAGR driven by cost synergies, rapid commercial execution, and newly unlocked access to a global customer base and adjacencies..."
Read the full Bull Case to see why Waters could be undervalued
Bear case: 15% overvalued
"While the BD Biosciences and Diagnostic Solutions acquisition brings access to high-growth adjacencies and promised $290 million in revenue synergies, integration risks, uneven execution or cultural clashes could slow realization of these synergies, potentially delaying anticipated operating margin expansion and EPS growth..."
Read the full Bear Case to see why Waters could be overvalued
Do you think there's more to the story for Waters? Head over to our Community to see what others are saying!
The Bottom Line
For Waters, the Discounted Cash Flow (DCF) intrinsic value points to undervaluation, while the P/S comparison suggests the stock is overvalued relative to peers. That gap reflects a clash between what long term cash flows could support and what current growth expectations and sentiment have already priced into the multiple.
Broader valuation checks remain weak despite the supportive DCF signal, so the market is far from unanimous. The key question from here is whether Waters can deliver the revenue growth and margins needed to justify both the cash flow assumptions and the premium sales multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com